A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes.
G-CSF
MDS
Plerixafor
azacitidine
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
pubmed:
21
1
2021
medline:
25
6
2021
entrez:
20
1
2021
Statut:
ppublish
Résumé
Interactions between the bone marrow microenvironment and MDS tumor clones play a role in pathogenesis and response to treatment. We hypothesized G-CSF and plerixafor may enhance sensitivity to azacitidine in MDS. Twenty-eight patients with MDS were treated with plerixafor, G-CSF and azacitidine with a standard 3 + 3 design. Subjects received G-CSF 10 mcg/kg D1-D8, plerixafor D4-D8, and azacitidine 75 mg/m
Identifiants
pubmed: 33467957
doi: 10.1080/10428194.2021.1872068
pmc: PMC8178174
mid: NIHMS1670932
doi:
Substances chimiques
Benzylamines
0
Cyclams
0
Heterocyclic Compounds
0
Granulocyte Colony-Stimulating Factor
143011-72-7
Azacitidine
M801H13NRU
plerixafor
S915P5499N
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1441-1449Subventions
Organisme : NCI NIH HHS
ID : L30 CA153393
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA132269
Pays : United States
Organisme : NCI NIH HHS
ID : K12 CA167540
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA152329
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA091842
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000448
Pays : United States
Organisme : NHLBI NIH HHS
ID : K12 HL087107
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002345
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA141523
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA210084
Pays : United States
Références
Lancet Oncol. 2009 Mar;10(3):223-32
pubmed: 19230772
Blood. 2007 Jan 15;109(2):786-91
pubmed: 16888090
Haematologica. 2018 Aug;103(8):1308-1316
pubmed: 29724902
Blood. 2017 May 11;129(19):2680-2692
pubmed: 28292947
Science. 2008 Dec 19;322(5909):1861-5
pubmed: 19095944
Best Pract Res Clin Haematol. 2004 Dec;17(4):543-57
pubmed: 15494293
Blood. 2009 Jun 11;113(24):6215-24
pubmed: 18955566
Blood. 2009 Jun 11;113(24):6206-14
pubmed: 19050309
Blood. 1997 Dec 15;90(12):4710-8
pubmed: 9389686
Leukemia. 1999 Aug;13(8):1207-13
pubmed: 10450748
N Engl J Med. 2003 Aug 21;349(8):743-52
pubmed: 12930926
Blood. 1994 Apr 15;83(8):2086-92
pubmed: 7512838
Med Oncol. 2012 Jun;29(2):1202-8
pubmed: 21556934
J Clin Oncol. 2011 Feb 10;29(5):591-9
pubmed: 21220598
Blood. 1998 May 15;91(10):3607-15
pubmed: 9572995
Front Biosci (Landmark Ed). 2014 Jan 01;19:171-80
pubmed: 24389180
Mol Cancer Ther. 2006 Dec;5(12):3113-21
pubmed: 17172414
Onco Targets Ther. 2013 Sep 30;6:1347-61
pubmed: 24124379
Cancer. 2007 Mar 15;109(6):1152-6
pubmed: 17315232
Blood. 2009 Jun 4;113(23):5720-6
pubmed: 19363221
Bone Marrow Transplant. 2015 Jul;50(7):939-946
pubmed: 25867648
Leukemia. 2009 Dec;23(12):2233-41
pubmed: 19727127
Leukemia. 2008 Dec;22(12):2151-5158
pubmed: 18769446
Ann Hematol. 2004 Aug;83(8):498-503
pubmed: 15156346
J Exp Med. 2005 Apr 18;201(8):1307-18
pubmed: 15837815
Med Oncol. 2013 Mar;30(1):341
pubmed: 23263827
Leuk Res. 2012 Mar;36(3):281-6
pubmed: 21802140
Cell Death Dis. 2012 Oct 04;3:e396
pubmed: 23034331
J Clin Oncol. 2009 Oct 1;27(28):4767-73
pubmed: 19720922
Leuk Lymphoma. 2013 Sep;54(9):2003-7
pubmed: 23270581
Blood. 2012 Apr 26;119(17):3917-24
pubmed: 22308295
Blood. 2004 Jul 15;104(2):550-7
pubmed: 15054042
Blood Adv. 2019 Mar 26;3(6):875-883
pubmed: 30890544
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Cancer. 2011 Jun 15;117(12):2697-702
pubmed: 21656747
Leuk Res. 2015 Oct;39(10):1020-7
pubmed: 26276090
Hematology. 2014 Jun;19(4):232-8
pubmed: 23905984
Blood. 2009 Aug 13;114(7):1331-9
pubmed: 19141863
Nat Immunol. 2002 Jul;3(7):687-94
pubmed: 12068293